Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90010 with temozolomide with or without radiotherapy in newly diagnosed glioblastoma
NL-OMON54644Phase 1Recruiting
- Sponsor
- Celgene Corporation
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of trotabresib in glioblastoma (GBM) and glioma (4 arms), sponsored by Celgene Corporation. Primary endpoints: Safety and tolerability of CC-90010 with temozolomide as adjuvant therapy, Safety and tolerability of CC-90010 with temozolomide plus radiotherapy as concomitant therapy and 2 more. Started Dec 2020; status: recruiting.
02
Drugs
trotabresib
03
Conditions
glioblastoma (GBM)glioma
Beyond the preview
Go deeper on NL-OMON54644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54644.